Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic | Infectious Diseases | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME
Key Points

Question  Are the belief in having had COVID-19 infection and actually having had the infection as verified by SARS-CoV-2 serology testing associated with persistent physical symptoms during the COVID-19 pandemic?

Findings  In this cross-sectional analysis of 26 823 adults from the population-based French CONSTANCES cohort during the COVID-19 pandemic, self-reported COVID-19 infection was associated with most persistent physical symptoms, whereas laboratory-confirmed COVID-19 infection was associated only with anosmia. Those associations were independent from self-rated health or depressive symptoms.

Meaning  Findings suggest that persistent physical symptoms after COVID-19 infection should not be automatically ascribed to SARS-CoV-2; a complete medical evaluation may be needed to prevent erroneously attributing symptoms to the virus.

Abstract

Importance  After an infection by SARS-CoV-2, many patients present with persistent physical symptoms that may impair their quality of life. Beliefs regarding the causes of these symptoms may influence their perception and promote maladaptive health behaviors.

Objective  To examine the associations of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms (eg, fatigue, breathlessness, or impaired attention) in the general population during the COVID-19 pandemic.

Design, Setting, and Participants  Participants in this cross-sectional analysis were 26 823 individuals from the French population-based CONSTANCES cohort, included between 2012 and 2019, who took part in the nested SAPRIS and SAPRIS-SERO surveys. Between May and November 2020, an enzyme-linked immunosorbent assay was used to detect anti–SARS-CoV-2 antibodies. Between December 2020 and January 2021, the participants reported whether they believed they had experienced COVID-19 infection and had physical symptoms during the previous 4 weeks that had persisted for at least 8 weeks. Participants who reported having an initial COVID-19 infection only after completing the serology test were excluded.

Main Outcomes and Measures  Logistic regressions for each persistent symptom as the outcome were computed in models including both self-reported COVID-19 infection and serology test results and adjusting for age, sex, income, and educational level.

Results  Of 35 852 volunteers invited to participate in the study, 26 823 (74.8%) with complete data for serologic testing and self-reported infection were included in the present study (mean [SD] age, 49.4 [12.9] years; 13 731 women [51.2%]). Self-reported infection was positively associated with persistent physical symptoms, with odds ratios ranging from 1.44 (95% CI, 1.08-1.90) to 16.61 (95% CI, 10.30-26.77) except for hearing impairment (odds ratio, 1.38; 95% CI, 0.76-2.51), joint pain (odds ratio, 1.32; 95% CI, 0.98-1.80) and sleep problems (odds ratio, 1.12; 95% CI, 0.87-1.44). A serology test result positive for SARS-COV-2 was positively associated only with persistent anosmia (odds ratio, 2.59; 95% CI, 1.57-4.28), even when restricting the analyses to participants who attributed their symptoms to COVID-19 infection. Further adjusting for self-rated health or depressive symptoms yielded similar results. There was no significant interaction between belief and serology test results.

Conclusions and Relevance  The findings of this cross-sectional analysis of a large, population-based French cohort suggest that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection. Further research in this area should consider underlying mechanisms that may not be specific to the SARS-CoV-2 virus. A medical evaluation of these patients may be needed to prevent symptoms due to another disease being erroneously attributed to “long COVID.”

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: September 17, 2021.

Published Online: November 8, 2021. doi:10.1001/jamainternmed.2021.6454

Correction: This article was corrected on March 21, 2022, to fix errors in the article and Supplement 1.

Corresponding Author: Cédric Lemogne, MD, PhD, Service de Psychiatrie de l’adulte, Hôpital Hôtel-Dieu, 1 place du Parvis Notre-Dame, 75004 Paris, France (cedric.lemogne@aphp.fr).

Author Contributions: Drs Matta and Lemogne had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Acquisition, analysis, or interpretation of data: Matta, Wiernik, Robineau, Carrat, Touvier, de Lamballerie, Blanché, Deleuze, Hoertel, Ranque, Goldberg, Lemogne.

Drafting of the manuscript: Matta, Lemogne.

Critical revision of the manuscript for important intellectual content: Matta, Wiernik, Robineau, Carrat, Touvier, Severi, de Lamballerie, Blanché, Deleuze, Gouraud, Hoertel, Ranque, Goldberg, Zins.

Statistical analysis: Matta, Robineau, Hoertel.

Obtained funding: Blanché, Zins.

Administrative, technical, or material support: Blanché, Deleuze, Gouraud, Goldberg, Zins.

Supervision: Carrat, Touvier, Blanché, Gouraud, Goldberg, Lemogne.

Conflict of Interest Disclosures: Dr Robineau reported personal fees and nonfinancial support from Gilead, ViiV Healthcare, and Merck Sharp & Dohme Corp outside the submitted work. Dr Carrat reported personal fees from Sanofi outside the submitted work. Dr de Lamballerie reported grants from the French Ministry of Research and the French Institute of Health and Medical Research during the conduct of the study. Dr Hoertel reported personal fees and nonfinancial support from Lundbeck outside the submitted work. Dr Lemogne reported personal fees from Boehringer Ingelheim, Janssen-Cilag, Lundbeck, and Otsuka Pharmaceutical outside the submitted work. No other disclosures were reported.

Funding/Support: The CONSTANCES cohort benefits from grant ANR-11-INBS-0002 from the French National Research Agency. CONSTANCES is supported by the Caisse Nationale d’Assurance Maladie, the French Ministry of Health, the Ministry of Research, and the Institut National de la Santé et de la Recherche Médicale (INSERM). CONSTANCES is also partly funded by AstraZeneca, Lundbeck, L’Oréal, and Merck Sharp & Dohme Corp. The Santé, Pratiques, Relations et Inégalités Socials en Population Générale Pendant la Crise COVID-19 (SAPRIS) and SAPRIS-Sérologie (SERO) study was supported by grants ANR-10-COHO-06 and ANR-20-COVI-000 from the Agence Nationale de la Recherche; grant 20DMIA014-0 from Santé Publique France; grant 20RR052-00 from the Fondation pour la Recherche Médicale; and grant C20-26 from INSERM.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Group Information: A complete list of the members of the SAPRIS-SERO study group appears in Supplement 2.

Additional Contributions: Céline Ribet, PhD, Mireille Pellicer, MD, Laura Quintin, MSc, Stephane Le Got, MSc, all from the CONSTANCES cohort, and Céline Dorival, PhD, and Jerôme Nicol, MSc, from INSERM Institut Pierre Louis d’Epidémiologie et de Santé Publique, substantially contributed to data collection for this work.

References
1.
Nehme  M , Braillard  O , Alcoba  G ,  et al; COVICARE TEAM.  COVID-19 symptoms: longitudinal evolution and persistence in outpatient settings.   Ann Intern Med. 2021;174(5):723-725. doi:10.7326/M20-5926 PubMedGoogle ScholarCrossref
2.
Al-Aly  Z , Xie  Y , Bowe  B .  High-dimensional characterization of post-acute sequelae of COVID-19.   Nature. 2021;594(7862):259-264. doi:10.1038/s41586-021-03553-9 PubMedGoogle ScholarCrossref
3.
Crook  H , Raza  S , Nowell  J , Young  M , Edison  P .  Long covid—mechanisms, risk factors, and management.   BMJ. 2021;374:n1648. doi:10.1136/bmj.n1648 PubMedGoogle Scholar
4.
Mahase  E .  Covid-19: what do we know about “long covid”?   BMJ. 2020;370:m2815. doi:10.1136/bmj.m2815 PubMedGoogle Scholar
5.
Nalbandian  A , Sehgal  K , Gupta  A ,  et al.  Post-acute COVID-19 syndrome.   Nat Med. 2021;27(4):601-615. doi:10.1038/s41591-021-01283-z PubMedGoogle ScholarCrossref
6.
Yelin  D , Wirtheim  E , Vetter  P ,  et al.  Long-term consequences of COVID-19: research needs.   Lancet Infect Dis. 2020;20(10):1115-1117. doi:10.1016/S1473-3099(20)30701-5 PubMedGoogle ScholarCrossref
7.
CONSTANCES. 220 000 Volontaires pour améliorer la santé de demain [in French]. 2021. Accessed October 6, 2021. https://www.constances.fr/
8.
Zins  M , Goldberg  M ; CONSTANCES team.  The French CONSTANCES population-based cohort: design, inclusion and follow-up.   Eur J Epidemiol. 2015;30(12):1317-1328. doi:10.1007/s10654-015-0096-4 PubMedGoogle ScholarCrossref
9.
Carrat  F , Touvier  M , Severi  G ,  et al; SAPRIS study group.  Incidence and risk factors of COVID-19-like symptoms in the French general population during the lockdown period: a multi-cohort study.   BMC Infect Dis. 2021;21(1):169. doi:10.1186/s12879-021-05864-8 PubMedGoogle ScholarCrossref
10.
Carrat  F , de Lamballerie  X , Rahib  D ,  et al; SAPRIS and SAPRIS-SERO study groups.  Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study.   Int J Epidemiol.Published online July 19, 2021. doi:10.1093/ije/dyab110PubMedGoogle Scholar
11.
Patel  EU , Bloch  EM , Clarke  W ,  et al.  Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers.   J Clin Microbiol. 2021;59(2):e02257-e20. doi:10.1128/JCM.02257-20 PubMedGoogle ScholarCrossref
12.
Morin  AJ , Moullec  G , Maïano  C , Layet  L , Just  JL , Ninot  G .  Psychometric properties of the Center for Epidemiologic Studies Depression Scale (CES-D) in French clinical and nonclinical adults.   Rev Epidemiol Sante Publique. 2011;59(5):327-340. doi:10.1016/j.respe.2011.03.061 PubMedGoogle ScholarCrossref
13.
Havervall  S , Rosell  A , Phillipson  M ,  et al.  Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers.   JAMA. 2021;325(19):2015-2016. doi:10.1001/jama.2021.5612 PubMedGoogle ScholarCrossref
14.
Amin-Chowdhury  Z , Ladhani  SN .  Causation or confounding: why controls are critical for characterizing long COVID.   Nat Med. 2021;27(7):1129-1130. doi:10.1038/s41591-021-01402-w PubMedGoogle ScholarCrossref
15.
Scherlinger  M , Felten  R , Gallais  F ,  et al.  Refining “Long-COVID” by a prospective multimodal evaluation of patients with long-term symptoms attributed to SARS-CoV-2 infection.   Infect Dis Ther. 2021;10(3):1747-1763. doi:10.1007/s40121-021-00484-w PubMedGoogle ScholarCrossref
16.
Sudre  CH , Murray  B , Varsavsky  T ,  et al.  Attributes and predictors of long COVID.   Nat Med. 2021;27(4):626-631. doi:10.1038/s41591-021-01292-y PubMedGoogle ScholarCrossref
17.
García-Abellán  J , Padilla  S , Fernández-González  M ,  et al.  Antibody response to SARS-CoV-2 is associated with long-term clinical outcome in patients with COVID-19: a longitudinal study.   J Clin Immunol. 2021;41(7):1490-1501. doi:10.1007/s10875-021-01083-7 PubMedGoogle ScholarCrossref
18.
Datta  SD , Talwar  A , Lee  JT .  A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: illness beyond acute infection and public health implications.   JAMA. 2020;324(22):2251-2252. doi:10.1001/jama.2020.22717 PubMedGoogle ScholarCrossref
19.
Wiech  K .  Deconstructing the sensation of pain: the influence of cognitive processes on pain perception.   Science. 2016;354(6312):584-587. doi:10.1126/science.aaf8934 PubMedGoogle ScholarCrossref
20.
Henningsen  P , Gündel  H , Kop  WJ ,  et al; EURONET-SOMA Group.  Persistent physical symptoms as perceptual dysregulation: a neuropsychobehavioral model and its clinical implications.   Psychosom Med. 2018;80(5):422-431. doi:10.1097/PSY.0000000000000588 PubMedGoogle ScholarCrossref
21.
Klem  F , Wadhwa  A , Prokop  LJ ,  et al.  Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis.   Gastroenterology. 2017;152(5):1042-1054. doi:10.1053/j.gastro.2016.12.039 PubMedGoogle ScholarCrossref
22.
Tran  VT , Riveros  C , Clepier  B ,  et al.  Development and validation of the long covid symptom and impact tools, a set of patient-reported instruments constructed from patients’ lived experience.   Clin Infect Dis. Published online April 29, 2021. doi:10.1093/cid/ciab352PubMedGoogle Scholar
23.
Henningsen  P , Zipfel  S , Sattel  H , Creed  F .  Management of functional somatic syndromes and bodily distress.   Psychother Psychosom. 2018;87(1):12-31. doi:10.1159/000484413 PubMedGoogle ScholarCrossref
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close